Why Akeso’s gumokimab approval could sharpen China’s psoriasis biologics race
Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and IL-17 competition.
Pharma & Biotech
Pharma & Biotech
Kelun-Biotech’s ASCO 2026 data strengthens China’s next wave of targeted cancer drugs
Kelun-Biotech’s RET lung cancer data looks strong, but CNS durability and global competition will decide its real impact.
Pharma & Biotech
Can Leads Biolabs turn Opamtistomig into a frontline EP-NEC treatment contender?
EP-NEC has no approved drug worldwide. Leads Biolabs now has to prove Opamtistomig can turn rare-tumor urgency into regulatory momentum.
Pharma & Biotech
Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market
ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.
Pharma & Biotech
Can zemprocitinib help Lynk Pharmaceuticals break into China’s crowded atopic dermatitis market?
Lynk Pharmaceuticals won NMPA acceptance for zemprocitinib in atopic dermatitis. Read what this filing changes, and what risks still remain.
Pharma & Biotech
GSK’s Trelegy Ellipta becomes China’s first approved triple therapy for both asthma and COPD
GSK plc has received regulatory approval from China’s National Medical Products Administration (NMPA) to market Trelegy Ellipta, a once-daily inhaled combination of fluticasone furoate, umeclidinium, and vilanterol, for the treatment of adult patients with uncontrolled asthma. This decision expands Trelegy Ellipta’s label beyond its existing indication in chronic obstructive pulmonary disease (COPD), making it the
Pharma & Biotech
Akeso’s gumokimab advances to NMPA review in ankylosing spondylitis: Is China’s IL-17 race entering a new phase?
Akeso’s gumokimab enters NMPA review for ankylosing spondylitis after Phase 3 success. Find out what this could mean for IL-17 therapies in China.